Bridging the Cell and Gene Therapy Gap Between Manufacture and Supply Chain
Summary: With the rise of the development of cell and gene therapies and their associated clinical trials, it is becoming increasingly important to bridge the knowledge and service gaps from the manufacturing of these advanced therapies to the end-to-end supply chain management. A survey was recently conducted by Catalent and Fierce Biotech to better understand the current perceptions of these gaps by individuals in the CGT industry, including the specialized supply chain needs associated with these types of studies.